TORONTO, May 20, 2021 (GLOBE NEWSWIRE) — Field Trip Health Ltd. (CSE: FTRP; FTRP.WT; OTCQX: FTRPF) (“Field Trip“), a leader in the development and delivery of psychedelic therapies, is pleased to announce the appointment of former US Senate Majority Leader Tom Daschle as a Special Adviser to the Company.
Joseph del Moral, Chief Executive Officer of Field Trip, said, “Senator Daschle has participated in the development and debate of almost every major public policy issue of the last three decades and is a pre-eminent expert on health policy reform. With the psychedelics industry now gaining significant traction among scientists and an increasing number of clinical trials launching, we are looking forward to working with Senator Daschle to advance society’s understanding of psychedelics and their potential to revolutionize our approach to mental, emotional and behavioral health.”
“There is a paradigm shift underway in our understanding about the role that psychedelics can play in the field of mental health and well-being, being primarily driven by scientists that are dedicating their time and energy to studying and understanding these molecules. Given the urgent need to respond to the global mental health crisis, as well as the impending mental health fallout from the COVID-19 pandemic, it is of vital importance that public policy keeps up with these advances. Field Trip has proven itself to be a leader in this industry and I look forward to partnering with them to advance this mission,” said Senator Tom Daschle.
Senator Daschle is one of the longest serving Senate Democratic leaders in history and one of only two to serve twice as both Majority and Minority Leader. In 1978, he was elected to the U.S. House of Representatives, where he served eight years. In 1986, he was elected to the U.S. Senate and was chosen as Senate Democratic Leader in 1994. Senator Daschle is also the Founder and CEO of the Daschle Group, a Public Policy Advisory of Baker Donelson and a legal and government affairs firm that advises clients on a broad array of economic, policy and political issues.
Senator Daschle is the co-founder of the Bipartisan Policy Center and co-chair of the National Institute for Civil Discourse. He is also Vice Chair for the National Democratic Institute and on the Board of Directors at the Center for American Progress. He also serves on the board of the Edward M. Kennedy Institute and the LBJ Foundation and is a member of the Health Policy and Management Executive Council at the Harvard School of Public Health and the Council of Foreign Relations.
Born in Aberdeen, South Dakota, Senator Daschle graduated from South Dakota State University and then served for three years as an intelligence officer in the U.S. Air Force Strategic Command. After leaving the Senate in 2005, Senator Daschle joined Alston & Bird LLP as a special policy advisor and then went on to work in the same role at the DLA Piper before establishing The Daschle Group.
In consideration of the services, Senator Daschle will be receiving a stipend and options consistent with grants made to the members of the board of directors of Field Trip.
About Field Trip Health Ltd.
Field Trip is a global leader in the development and delivery of psychedelic therapies. With our Field Trip Discovery division leading the development of the next generation of psychedelic molecules and conducting advanced research on plant-based psychedelics and our Field Trip Health division building centers for psychedelic therapies opening across North America and Europe along with the digital and technological tools that will enable massive scale, we help people in need with a simple, evidence-based way to heal and heighten engagement with the world.
Follow us on Twitter and Instagram: @fieldtriphealth
To receive company updates about Field Trip and to be added to the email distribution list please sign up here.
For further information, contact Ronan Levy, Executive Chairman and a Director at Field Trip, at 1 (833) 833-1967.
Cautionary Note Regarding Forward-Looking Information.
This release includes forward-looking information within the meaning of Canadian securities laws regarding Field Trip and its business, which may include, but are not limited to, statements relating to Field Trip’s intended use of proceeds from the Offering. Often but not always, forward-looking information can be identified by the use of words such as “expect”, “intends”, “anticipated”, “believes” or variations (including negative variations) of such words and phrases, or state that certain actions, events or results “may”, “could”, “would” or “will” be taken, occur or be achieved. Such statements are based on the current expectations and views of future events of the management of Field Trip, and are based on assumptions and subject to risks and uncertainties. Although the management of Field Trip believes that the assumptions underlying these statements are reasonable, they may prove to be incorrect. The forward-looking events and circumstances discussed in this release may not occur and could differ materially as a result of known and unknown risk factors and uncertainties affecting the companies, including risks regarding the COVID-19 epidemic, the medical clinic industry, market conditions, economic factors, management’s ability to manage and to operate the business and the equity markets generally. Although Field Trip has attempted to identify important factors that could cause actual actions, events or results to differ materially from those described in forward-looking statements, there may be other factors that cause actions, events or results to differ from those anticipated, estimated or intended. Accordingly, readers should not place undue reliance on any forward-looking statements or information. No forward-looking statement can be guaranteed. Except as required by applicable securities laws, forward-looking statements speak only as of the date on which they are made and Field Trip does not undertake any obligation to publicly update or revise any forward-looking statement, whether as a result of new information, future events, or otherwise.
Neither the Canadian Securities Exchange, nor its Regulation Services Provider, nor the OTC Markets have approved the contents of this release or accept responsibility for the adequacy or accuracy of this release.
Nick Opich / McKenna Miller
KCSA Strategic Communications
212-896-1206 / 347-487-6197
KCSA Strategic Communications
SOURCE Field Trip Health Ltd.